PMID- 12377960
OWN - NLM
STAT- MEDLINE
DCOM- 20021024
LR  - 20161102
IS  - 0732-183X (Print)
IS  - 0732-183X (Linking)
VI  - 20
IP  - 20
DP  - 2002 Oct 15
TI  - Vaccination of metastatic melanoma patients with autologous tumor-derived heat 
      shock protein gp96-peptide complexes: clinical and immunologic findings.
PG  - 4169-80
AB  - PURPOSE: To determine the immunogenicity and antitumor activity of a vaccine 
      consisting of autologous, tumor-derived heat shock protein gp96-peptide complexes 
      (HSPPC-96, Oncophage; Antigenics, Inc, Woburn, MA) in metastatic (American Joint 
      Committee on Cancer stage IV) melanoma patients. PATIENTS AND METHODS: Sixty-four 
      patients had surgical resection of metastatic tissue required for vaccine 
      production, 42 patients were able to receive the vaccine, and 39 were assessable 
      after one cycle of vaccination (four weekly injections). In 21 patients, a second 
      cycle (four biweekly injections) was given because no progression occurred. 
      Antigen-specific antimelanoma T-cell response was assessed by enzyme-linked 
      immunospot (ELISPOT) assay on peripheral blood mononuclear cells (PBMCs) obtained 
      before and after vaccination. Immunohistochemical analyses of tumor tissues were 
      also performed. RESULTS: No treatment-related toxicity was observed. Of 28 
      patients with measurable disease, two had a complete response (CR) and three had 
      stable disease (SD) at the end of follow-up. Duration of CR was 559+ and 703+ 
      days, whereas SD lasted for 153, 191, and 272 days, respectively. ELISPOT assay 
      with PBMCs of 23 subjects showed a significantly increased number of 
      postvaccination melanoma-specific T-cell spots in 11 patients, with clinical 
      responders displaying a high frequency of increased T-cell activity. 
      Immunohistochemical staining of melanoma tissues from which vaccine was produced 
      revealed high expression of both HLA class I and melanoma antigens in seven of 
      eight clinical responders (two with CR, three with SD, and the three with 
      long-term disease-free survival) and in four of 12 nonresponders. CONCLUSION: 
      Vaccination of metastatic melanoma patients with autologous HSPPC-96 is feasible 
      and devoid of significant toxicity. This vaccine induced clinical and 
      tumor-specific T-cell responses in a significant minority of patients.
FAU - Belli, Filiberto
AU  - Belli F
AD  - Unit of General Surgery 2, Istituto Nazionale Tumori, Milan, Italy.
FAU - Testori, Alessandro
AU  - Testori A
FAU - Rivoltini, Licia
AU  - Rivoltini L
FAU - Maio, Michele
AU  - Maio M
FAU - Andreola, Giovanna
AU  - Andreola G
FAU - Sertoli, Mario Roberto
AU  - Sertoli MR
FAU - Gallino, Gianfrancesco
AU  - Gallino G
FAU - Piris, Adriano
AU  - Piris A
FAU - Cattelan, Alessandro
AU  - Cattelan A
FAU - Lazzari, Ivano
AU  - Lazzari I
FAU - Carrabba, Matteo
AU  - Carrabba M
FAU - Scita, Giorgio
AU  - Scita G
FAU - Santantonio, Cristina
AU  - Santantonio C
FAU - Pilla, Lorenzo
AU  - Pilla L
FAU - Tragni, Gabrina
AU  - Tragni G
FAU - Lombardo, Claudia
AU  - Lombardo C
FAU - Arienti, Flavio
AU  - Arienti F
FAU - Marchiano, Alfonso
AU  - Marchiano A
FAU - Queirolo, Paola
AU  - Queirolo P
FAU - Bertolini, Francesco
AU  - Bertolini F
FAU - Cova, Agata
AU  - Cova A
FAU - Lamaj, Elda
AU  - Lamaj E
FAU - Ascani, Lucio
AU  - Ascani L
FAU - Camerini, Roberto
AU  - Camerini R
FAU - Corsi, Marco
AU  - Corsi M
FAU - Cascinelli, Natale
AU  - Cascinelli N
FAU - Lewis, Jonathan J
AU  - Lewis JJ
FAU - Srivastava, Pramod
AU  - Srivastava P
FAU - Parmiani, Giorgio
AU  - Parmiani G
LA  - eng
GR  - 84479/PHS HHS/United States
PT  - Clinical Trial
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - J Clin Oncol
JT  - Journal of clinical oncology : official journal of the American Society of 
      Clinical Oncology
JID - 8309333
RN  - 0 (Antigens, Neoplasm)
RN  - 0 (Cancer Vaccines)
RN  - 0 (HLA Antigens)
RN  - 0 (Heat-Shock Proteins)
SB  - IM
EIN - J Clin Oncol 2002 Dec 1;20(23):4610
CIN - J Clin Oncol. 2002 Oct 15;20(20):4139-40. PMID: 12377956
MH  - Adult
MH  - Aged
MH  - Antigens, Neoplasm/immunology
MH  - Cancer Vaccines/*immunology/*therapeutic use
MH  - Female
MH  - HLA Antigens/*immunology
MH  - Heat-Shock Proteins/*immunology
MH  - Humans
MH  - Immunoassay/methods
MH  - Immunohistochemistry
MH  - *Immunotherapy
MH  - Male
MH  - Melanoma/immunology/pathology/*therapy
MH  - Middle Aged
MH  - Neoplasm Metastasis
MH  - Remission Induction
MH  - Skin Neoplasms/immunology/pathology/*therapy
MH  - Survival Analysis
MH  - T-Lymphocytes/immunology
EDAT- 2002/10/16 04:00
MHDA- 2002/10/31 04:00
CRDT- 2002/10/16 04:00
PHST- 2002/10/16 04:00 [pubmed]
PHST- 2002/10/31 04:00 [medline]
PHST- 2002/10/16 04:00 [entrez]
AID - 10.1200/JCO.2002.09.134 [doi]
PST - ppublish
SO  - J Clin Oncol. 2002 Oct 15;20(20):4169-80. doi: 10.1200/JCO.2002.09.134.